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Abstract
Background: Exosomes, small extracellular vesicles of endosomal origin, have been suggested to be involved in
both the metabolism and aggregation of Alzheimer’s disease (AD)-associated amyloid β-protein (Aβ). Despite their
ubiquitous presence and the inclusion of components which can potentially interact with Aβ, the role of exosomes
in regulating synaptic dysfunction induced by Aβ has not been explored.
Results: We here provide in vivo evidence that exosomes derived from N2a cells or human cerebrospinal fluid can
abrogate the synaptic-plasticity-disrupting activity of both synthetic and AD brain-derived Aβ. Mechanistically, this
effect involves sequestration of synaptotoxic Aβ assemblies by exosomal surface proteins such as PrP
C rather than
Aβ proteolysis.
Conclusions: These data suggest that exosomes can counteract the inhibitory action of Aβ, which contributes to
perpetual capability for synaptic plasticity.
Keywords: Alzheimer’s disease, Aβ, Exosomes, Synaptic plasticity, PrP
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Background
Alzheimer’s disease (AD) is characterized by progressive
cognitive decline [1,2]. Accumulating evidence has at-
tributed this deficit in the cognitive capacity of patients
and the potentially responsible failure in neural circuits
to an increased amount of amyloid β-protein (Aβ), par-
ticularly soluble Aβ oligomers rather than fibrils [3]. To
examine the mechanisms that underlie the synaptic dys-
function caused by Aβ oligomers, several laboratories
have utilized a cellular correlate of learning and memory -
long-term potentiation (LTP) - and have studied the ef-
fectiveness of different forms of soluble Aβ preparations
including Aβ-derived diffusible ligands (ADDLs) and AD
brain-derived Aβ [4-7]. As Aβ oligomers appear to exe-
cute their deleterious activities (i.e.,L T Pi m p a i r m e n t )b y
binding to their putative receptors such as p75 neurotro-
phin receptor, insulin receptor, and cellular prion protein
(PrP
C) [4,7-9], Aβ assemblies or their receptors have been
targeted to develop effective therapeutic strategies [6,10,11].
Despite enormous efforts, however, the molecular identity
and importance of intrinsic extracellular factors for
regulating the activities of Aβ oligomers are still poorly
understood.
In this study, we focused on one class of extracellular
vesicles, exosomes, as a potential regulator of Aβ and its
effects on synaptic plasticity in vivo. Exosomes are small
(30 - 100 nm diameter) membranous vesicles that are
secreted naturally into the extracellular space upon fu-
sion of multivesicular bodies with the plasma membrane
[12]. Although exosomes have been proposed to exert
multiple physiological roles [13] and are also known to
contain machinery to synthesize, degrade and induce ag-
gregation of Aβ [14-16], whether these factors in exo-
somes increase or decrease the deleterious actions of Aβ
is a matter of debate [15-18].
Direct assessment of the effect of exosomes on the ac-
tivity of synaptotoxic Aβ has been impeded by the diffi-
culty in controlling their levels in vivo. Here, we have
manipulated the concentration of exosomes in the brain
by infusing exosomes intracerebroventricularly (i.c.v.) and
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synaptic plasticity. We find that exosomes neutralize the
synaptic-plasticity disrupting activities of Aβ in vivo,a n d
also show that these effects are primarily the result of the
sequestration of Aβ oligomers via exosomal surface pro-
teins such as PrP
C. The potential relevance of our findings
to AD is underscored by our observation that exosomes
from human cerebrospinal fluid (CSF) prevent the impair-
ment of LTP that is mediated by Aβ derived from AD
brain extracts.
Results
Exosomes attenuated ADDL-mediated LTP inhibition
We investigated whether exosomes affect Aβ-induced
LTP impairment in the CA1 region of the dorsal hippo-
campus in vivo.W eu s e dA D D L s[ 5 ]p r e p a r e df r o ms y n -
thetic Aβ1-42 and exosomes isolated from the conditioned
media of cultured N2a neuroblastoma cells (Figure 1). On
SDS-PAGE, ADDLs yielded 3 bands which migrated with
molecular weights of ~4 (monomer), ~12 (trimer) and 16
(tetramer) kDa (Figure 1A). By dynamic light scattering
(DLS), ADDLs contained a mixture of species with hydro-
dynamic radii (RH) ranging from ~10 to 30 nm (Figure 1B),
but by atomic force microscopy (AFM) only small (3 -
6 nm) globular structures were detected (Figure 1C, D).
The apparent size discrepancy for the Aβ species present
in our ADDL preparation is likely to result from technical
limits of the used methods. Specifically, since SDS-PAGE
is highly denaturing, it might not be suitable for determin-
ation of native sizes of Aβ assembly, but could be used to
distinguish the SDS-stable forms from labile Aβ species.
While AFM could be used to detect oligomeric forms of
Aβ, certain assemblies would not adhere to mica well
enough and as a result, were not detected. Nonetheless,
our characterization of ADDLs revealed the presence of a
heterogeneous mixture of different Aβ species, some of
which were at least partially stable in SDS and which
existed as small globular structures of 3 - 6 nm [5,19].
To prepare exosome fractions, we had excluded plasma
membrane-derived fragments and other non-exosomal
vesicles through the optimized procedures [20]. Contrast-
ing to the vesicles originated from Golgi body that float at
1.05 to 1.12 g/ml and endoplasmic reticulum-derived vesi-
cles at 1.18 to 1.25 g/ml, exosomes are the only vesicles
sizing 30~100 nm and gradient density ranging 1.13~
1.19 g/ml (Figure 1E) [12,20]. Exosomes are further de-
fined by their expression of marker proteins such as
Flotillin-1, Alix or PrP
C that are highly enriched in the
exosomal fractions (Figure 1E), their ultrastructure and
size (Figure 1F, G) [12]. Altogether, we verified that
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Figure 1 Characterization of ADDLs and exosomes used for biochemical and physiological experiments. (A) ADDLs were analyzed by
Western blotting using 6E10. SM, size markers (kDa). (B) DLS particle distribution analysis of ADDLs (red line) (14.3± 1.1 nm) and Aβ1-42 freshly
dissolved in 10 mM NaOH (black line) (6.4±0.3 nm) was expressed as hydrodynamic radii (RH). (C) A tapping AFM mode image of ADDLs (X-Y, 5 x 5 μm
with an inset displaying a z-range in color from 0 to 15 nm). (D) By AFM, only small (3 - 6 nm) globular structures were detected. (E) Exosomes isolated
from the conditioned medium of N2a cells had their density 1.13 g/ml to 1.19 g/ml, and contained the exosomal marker proteins Alix, Flotilin-1 and PrP
C.
Multiple (non-, mono- or di-) glycosylated PrP
C proteins were detected between 20~35 kDa on SDS-PAGE. (F) By EM, exosomes appeared as closed
vesicles of 30-120 nm in diameter (Scale bar: 100 nm), (G) a size range that agreed with that measured by DLS.
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somes [12,20].
In agreement with prior reports [5], high-frequency
stimulation (HFS) failed to trigger robust LTP in anes-
thetized rats that had received i.c.v. injection of ADDLs
(PBS +ADDL, 105 ±6%, n =4 vs. PBS+ PBS, 166 ±10%,
n =4 at 3 h post-HFS, P<0.001, one-way ANOVA with
post hoc Tukey; Figure 2A). Somewhat unexpectedly,
prior infusion of 4 μg exosomes markedly attenuated the
synaptic-plasticity-disrupting action of ADDLs. Indeed,
despite the administration of ADDLs, HFS now induced
robust LTP that was comparable to the control levels
and which remained stable for more than 3 h (Exo +
ADDL, 152 ±6%, n =5, P <0.01 vs. PBS+ ADDL; P >0.4
vs. PBS +PBS, one-way ANOVA with post hoc Tukey;
Figure 2A). Of note, the effect of exosomes against
ADDL-induced LTP inhibition was largely dependent
upon the amount of exosomes, producing a significant
effect when 4 μg or more was infused (Figure 2B). Unless
otherwise specified, therefore, we used 4 μge x o s o m e si n
the subsequent studies. In this condition, however, neither
exosomes nor ADDLs significantly affected baseline syn-
aptic transmission (Figure 2C). Exosomes might exert this
protective effect by enhancing LTP per se,a n d / o rf u n c -
tionally counteract the plasticity-disrupting effect of
ADDLs. When we examined the ability of exosomes to
convert decremental LTP into stable LTP or boost control
LTP, however, we did not detect any significant difference
on weak HFS-induced decremental LTP (PBS, 106±7%,
n=5 vs. Exo, 117±6%, n=4, P>0. 3, un pa ir ed t - te st ;
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Figure 2 Exosomes abrogate ADDL-mediated disruption of LTP. (A) Prior infusion of exosomes (4 μgi n5μl, asterisk) prevented ADDLs
(10 pmol in 5 μl, hash) inhibiting LTP. Animals received sequential injections of exosomes and ADDLs before the application of HFS (arrow). Insets
show representative traces at the color-matched time points. Calibrations: 1.5 mV and 10 ms for all traces. (B) Dose-dependent protective effect
of exosomes against ADDL-mediated disruption of LTP (0 μg Exo+ ADDL, 100±3%, n=5; 0.2 μg Exo+ ADDL, 105± 5%, n=4; 1 μg Exo+ADDL,
123±5%, n=4; 4 μg Exo+ADDL, 151±10%, n=6; 10 μg Exo+ADDL, 168±9%, n=4). Statistical significance was expressed as **, P<0.01 comparing
to control group injected with 0 μgE x o+A D D L .(C) Neither exosomes nor ADDLs (5 μl, asterisk) affected baseline excitatory synaptic transmission in
the CA1 area in vivo (PBS, n = 4; ADDL, n = 5; Exo, n = 4). (D) Exosomes (4 μgi n5μl, asterisk) did not enhance decremental or standard LTP. An
arrow indicates the time point of application of either weak HFS for decremental LTP or HFS for standard LTP, respectively. Insets and calibrations as in
A. Error bars, ± SEM.
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http://www.molecularbrain.com/content/6/1/47Figure 2D) or standard HFS-induced LTP (PBS, 172±
13%, n=5 vs. Exo, 175±8%, n=4, P> 0.8, unpaired t-test;
Figure 2D). Thus, direct facilitatory effects on the mag-
nitude of LTP are unlikely to account for the capability
of exosomes to rapidly abrogate the inhibitory effects of
ADDLs.
ADDLs are sequestered on the surface of exosomes
To address possible mechanisms underlying the protect-
ive action of exosomes against ADDL-induced LTP in-
hibition, we first examined whether exosomes degrade
Aβ, which could abrogate the plasticity-disrupting effect.
When we incubated ADDLs with exosomes in the same
ratio used for LTP experiments, this resulted in a loss of
the Aβ species that migrated at ~4 kDa (monomer) on
SDS-PAGE (32 ±13%, P< 0.01, n =5, Mann-Whitney U
test; Figure 3A). Unlike Aβ monomer, Aβ oligomers
were largely unaffected by the incubation with exosomes
(~12 kDa Aβ, 96 ±10%, P >0.5; ~16 kDa Aβ, 97± 5%,
P >0.05, n= 5, Mann-Whitney U test; Figure 3A), indi-
cating that exosomes did not effectively degrade Aβ olig-
omers at least over the time course of our experiments.
Although the reason for the loss of Aβ monomer is un-
clear, it could result from the degradation of authentic
Aβ monomer by exosomal proteases such as insulin-
degrading enzyme (IDE) [15,21]. However, since mono-
meric Aβ does not inhibit LTP [22] and IDE is not
believed to degrade plasticity-disrupting Aβ oligomers
[23], such degradation would not be expected to contrib-
ute to the rescue of the ADDL-mediated block of LTP.
On the other hand, exosomes might decrease free Aβ
oligomers available by shifting free Aβ to the exosome-
bound Aβ. We examined this possibility by incubating
ADDLs with exosomes and then physically separating
(by centrifugation) exosomes from unbound Aβ. A major
proportion of Aβ oligomers co-migrated with the exo-
somes that were readily pelleted with ultracentrifugation
whereas only a small fraction of free ADDLs remained
in the supernatant fraction (mean % of pelleted Aβ rela-
tive to total Aβ: PB S+A DDL, 7±2 % vs . Ex o+AD DL,
82±7%, P<0.05, n=3, Mann-Whitney U test; Figure 3B).
However, this could have resulted potentially from Aβ
assemblies that were simply pelleted to the exosome-
containing fraction after being aggregated by exosomes
[16], rather than being directly bound to exosomes.
Therefore, we have corroborated the direct binding of
Aβ assemblies and exosomes by directly pulling down
the exosome-bound Aβ after their in vitro incubation
(Additional file 1: Figure S1), which argues against the
possibility.
To elucidate the possible fate of Aβ oligomers follow-
ing binding onto exosomes, we have developed a partial
trypsinization protocol to degrade only proteins on the
outside of exosomes (see Methods for detailed infor-
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Figure 3 ADDLs bound to exosomes. (A) Immunoblots of ADDLs after incubation either with PBS or exosomes (left top). Exosomes present in
each lane were verified with Flotillin-1 (left bottom). Right, relative optical density (O.D.) of Aβ species. (B) Immunoblot results of in vitro binding
assay of Aβ and exosomes (left top). Either exosomes or ADDLs alone were loaded as controls. Left bottom, exosomes were also verified with an
exosomal marker Flotillin-1 (P, pellet; S, supernatant). Right, relative O.D. of pelleted Aβ. (C) Exosome-bound ADDLs remained accessible to digestion
by trypsin (left top). Limited proteolysis with trypsin resulted in cleavage of exosomal surface protein PrP
C, but not the intraluminal protein Alix (left,
middle and bottom). Very low amount of ADDLs remained after trypsin treatment and the levels of which were similar irrespective of the presence or
absence of exosomes (right, relative O.D. of Aβ). Error bars, ± SEM. Statistical significance was expressed as *, P<0.05; **, P<0. 01 .
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http://www.molecularbrain.com/content/6/1/47mation) and applied this method after the incubation of
exosomes and ADDLs. If ADDLs were internalized into
exosomes, the resultant ADDLs residing in the lumen of
exosomes should be resistant to trypsin, which would
likely leave more ADDLs remaining after the treatment
of trypsin. Inconsistent with this notion, the remaining
amount of ADDLs did not differ in the absence and
presence of exosomes (% of remaining Aβ after trypsini-
zation: PBS +ADDL, 12± 4% vs. Exo +ADDL, 17± 1%;
P =0.51, n =3, Mann-Whitney U test; Figure 3C). There-
fore, a major proportion of ADDLs remains on the sur-
face of exosomes even after binding to exosomes in the
time frame we examined, rather than being internalized
into exosomes. Collectively, it is reasonable to speculate
that the protective effect of exosomes against ADDL-
induced LTP impairment arises from sequestering and
immobilization of Aβ oligomers at the surface of
exosomes.
Exosomal surface proteins including PrP
C are required for
the protective role of exosomes against Aβ
To further investigate the direct interaction of ADDLs
with exosomes, we used trypsin in a mild condition (see
Methods for details) to assess whether exosomal surface
proteins were required for ADDL-neutralizing activity.
The partial trypsinization efficiently removed the exoso-
mal surface proteins while leaving the luminal protein
intact (Figure 4A), and without affecting the integrity of
exosomes (Figure 4B, C). Importantly, the trypsinized
exosomes were no longer capable of rescuing the
ADDL-mediated block of LTP (T
- Exo +ADDL, 161 ±
9%, n =5 vs. T
+ Exo +ADDL, 107 ±6%, n = 4, P<0.01,
one-way ANOVA with post hoc Tukey; Figure 4D), and
did not alter either LTP per se (T
+ Exo +PBS, 170 ±7%,
n=4,P>0.9 compared to PBS +PBS, one-way ANOVA
with post hoc Tukey; Figure 4D) or baseline synaptic
transmission (Figure 4E). In agreement with the LTP
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Figure 4 Exosomal surface proteins are essential for the protective role of exosomes against the synaptic-plasticity-disrupting action
of ADDLs. (A) Trypsinization (T
+) was effective in removing surface proteins (PrP
C and CD81), but not luminal protein (Alix) of N2a cell-derived
exosomes when compared to non-trypsinized (T
-) control. Top, representative blots and bottom, normalized mean O.D. of immunoblots, n=5.
(B) Trypsinized exosomes (T
+ Exo, red line) had similar sizes (74± 3 nm), compared with those of non-trypsinized exosomes (T
- Exo, black line)
(83±7 nm, P>0.05, n=3), as measured by DLS. (C) By EM, the structure and size of T
+ Exo were indistinguishable from T
- Exo (Scale bar: 100 nm).
(D) T
+ Exo (5 μl, asterisk) was unable to prevent the plasticity-disrupting-activity of ADDLs (10 pmol in 5 μl, hash), but which can be neutralized by
T
- Exo. An arrow indicates HFS application and insets show representative traces at the color-matched time points. Calibration: 1.5 mV and 10
ms. (E) Lack of effect of i.c.v. injection (asterisk) of T
+ Exo (n=4) on the stability of fEPSP recordings. (F) Comparing to T
- Exo, T
+ Exo showed a
reduced ability to sequester ADDLs. Left panel: representative immunoblot using antibodies against Aβ (6E10), Alix and Flotillin-1 (P, pellet; S,
supernatant). Right panel: mean % of ~12 and 16 kDa Aβ bound to exosomes (P) relative to total ~12 and 16 kDa Aβ (P+S). Error bars, ± SEM.
Statistical significance was expressed as *, P <0.05; **, P <0.01.
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http://www.molecularbrain.com/content/6/1/47results, trypsinized exosomes bound only a smaller frac-
tion of Aβ oligomers compared to non-trypsinized exo-
somes (T
- Exo+ADDL, 67±3% vs. T
+ Exo+ADDL, 24±
2%, P<0.01, n=5, Mann-Whitney U test; Figure 4F).
These data indicate that surface proteins of exosomes are
required for the sequestration of synaptotoxic Aβ assem-
blies, which is consistent with prior reports that binding
of Aβ oligomers to neuronal membranes is mediated by
trypsin-sensitive molecules [5].
Aβ oligomers bind to PrP
C, a cell membrane-bound
glycoprotein that express abundantly in the central ner-
vous system, specifically and with high affinity [6,7,24];
PrP
C was also known to be expressed at high levels on
exosomes [25,26]. Thus, we sought to examine whether
exosomal PrP
C contributes to the sequestration of ADDLs
by exosomes. To this end, we prepared exosomes from ei-
ther Prnp
+/+ (wild-type, PrP
C WT) or Prnp
-/- (PrP
C knock-
out, PrP
C KO) hippocampal cell lines [27] (Figure 5A-C).
Because we injected exogenously PrP
C WT or KO exo-
somes through i.c.v. to wild type rat throughout the study,
acute infusion of these exosomes into the brain can change
only PrP
C of extracellular exosomes alone, but not neuronal
PrP
C level of subject animals. Intriguingly, the effectiveness
of PrP
C KO exosomes in preventing ADDL-induced
LTP inhibition was significantly reduced compared with
that of WT exosomes (WT Exo+ADDL, 159±5%, n=6,
P<0.001 vs. PBS+ADDL, 101±5%, n=6; P<0. 05vs .KO
Exo+ADDL, 129±3%, n=5, one-way ANOVA with post
hoc Tukey; Figure 5D, E) and the binding of Aβ oligomers
to PrP
C KO exosomes was also significantly decreased
compared to WT exosomes (WT Exo+ADDL, 70±2%
vs. KO Exo+ADDL, 45±5%; P<0.01, n=5, Mann-
Whitney U test; Figure 5F). The finding that knock-out of
exosomal PrP
C reduced ADDL binding and the exosome-
induced rescue of LTP to a similar extent suggests that
both effects are mediated, at least in part, through PrP
C.
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C on the surface of exosomes is essential for ADDL-neutralizing activity of exosomes. (A) Exosomes prepared from PrP
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AD brain-derived Aβ from affecting LTP
Because it remains unknown whether Aβ assemblies
formed in vitro accurately represent Aβ species found in
human brain, we investigated if exosomes could prevent
the disruptive activity of the most disease-relevant form
of Aβ,A β extracted from AD brain. Aqueous extracts of
AD brain contained Aβ species which migrated on SDS-
PAGE as monomers and dimers (Figure 6A) and po-
tently inhibited LTP (Figure 6B, E and F). Consistent
with our previous reports [11], this inhibition of LTP
was attributable to Aβ but not any other components of
the AD extract since specific removal of Aβ reversed this
effect, whereas mock-immunodepletion did not (PBS +
AD-Aβ
+, 110 ±9%, n=5 vs. PBS+AD-Aβ
-, 176± 7%, n = 5,
P< 0.001, one-way ANOVA with post hoc Tukey; Figure 6B,
F). Importantly, the i.c.v. infusion of N2a cell-derived exo-
somes fully abrogated the inhibitory effect of Aβ-containing
AD brain extracts (Exo+AD-Aβ
+, 175± 9%, n= 7, P< 0.001
vs. PBS +AD-Aβ
+,o n e - w a yA N O V Aw i t hpost hoc Tukey;
F i g u r e6 B ,Ca n dF ) ,b u td i dn o ta f f e c tL T Pi n d u c e di nt h e
presence of Aβ-immunodepleted AD brain extracts (Exo +
AD-Aβ
-, 179 ± 10%, n = 5, P>0.05 vs. PBS+AD-Aβ
-,o n e -
way ANOVA with post hoc Tukey; Figure 6B, C and F).
Next, we tested whether human brain-derived exosomes
could also neutralize plasticity-disrupting forms of Aβ.T o
do this, we isolated exosomes from the CSF of healthy vol-
unteers (Figure 6D). Due to the limited amount of CSF
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digm to pre-incubating CSF exosomes with AD brain ex-
tracts and then injecting the mixture before HFS as
previously used [10]. When CSF exosomes (1 μg) were
pre-incubated with AD brain extracts, normal LTP was in-
duced whereas injection of the same Aβ-containing AD
brain extracts without exosomes consistently inhibited
LTP (huExo + AD-Aβ
+, 163 ± 14%, n = 5, P>0. 9 v s. PB S,
167±7%, n=4; P<0.01 vs. PBS+AD-Aβ
+,1 1 2±5 % ,n=
5, one-way ANOVA with post hoc Tukey; Figure 6E, F).
These results demonstrate that CSF-derived exosomes can
also protect LTP against the plasticity-disrupting activity
of AD brain-derived Aβ.
Discussion
Although cellular functions of exosomes in nervous sys-
tem are not completely understood, previous studies
have provided evidence that exosomes can participate in
paracrine delivery of biologically active and infectious
materials such as Aβ, PrP
C and α-synuclein [28-31]. It
was also suggested that lipid components or IDE on the
surface of exosomes were involved in the regulation of
Aβ by activating fibrillization or proteolysis [15,16,32,33].
Although those reports had suggested the potential in-
teraction between Aβ and exosomes, however, the phy-
siological role of exosomes remains largely unknown
particularly for Aβ-induced synaptotoxicity [15,16,18].
This would stem from the fact that the controlled ma-
nipulation of the levels of exosomes in the brain is very
difficult and thus the direct assessment of the putative
roles that exosomes exert has been hampered. Using an
infusion paradigm, we discovered that addition of exogen-
ous exosomes into brain can abrogate the synaptic-
plasticity-disrupting activities of Aβ, most likely through
direct sequestration of Aβ oligomers.
Whereas it is generally postulated that synaptic failure
in AD is caused by soluble Aβ assemblies, the molecular
mechanisms whereby Aβ assemblies are formed and
maintained for AD pathogenesis remains unclear yet [4].
Although we could not fully identify the molecular iden-
tity of synaptotoxic Aβ assemblies, we confirmed that
our Aβ preparations from synthetic Aβ1-42 peptide or
AD brain extraction can effectively inhibit synaptic plas-
ticity in vivo [5,6,11,34], which validated the efficacy of
the used experimental conditions. Furthermore, multiple
characterization assays that we used revealed the pres-
ence of a heterogeneous mixture of different sized Aβ
species and also relatively pure exosomal preparation,
consistent with previous reports [5,12,19,20]. In addition
to the protective effect of exosomes against synaptotoxic
activity of ADDLs, we found that exosomes were able to
ameliorate the plasticity-disrupting activity of the most
pathophysiologically-relevant form of Aβ,A β extracted
from AD brain. Interestingly, we had to inject at least 45
ng of ADDLs and only 18 pg of Aβ from AD brain to
produce potent inhibition of LTP. We and others have
previously reported that the potency of synthetic Aβ
used to disrupt the memory of learned behavior or to
impair LTP is usually several orders of magnitude higher
than that of naturally produced Aβ from the AD brain
or APP expressing-cultured cell lines [11,34,35]. The dif-
ferent potency of the two Aβ preparations used in the
present experiments likely reflects the fact that although
they contained similar concentrations of synaptic plasti-
city disrupting Aβ, other additional assemblies, that are
presumed to be relatively inactive, are present in higher
concentration in the ADDL preparation compared to AD
brain extracts.
The protective effect of exosomes against the synaptic-
plasticity-disrupting activity of Aβ leaves the question
about the underlying mechanisms. As Aβ itself is a sticky
protein and exosomes contain a variety of proteins and
lipid components, there are several possibilities including
non-specific proteolysis or sequestration such that a num-
ber of proteins, lipids, and membranous vesicles could
affect Aβ-mediated LTP inhibition. Throughout biochem-
ical experiments and in vivo electrophysiology, however,
we demonstrate that proteolysis of Aβ is unlikely account
for the protective effect; rather exosomes could sequester
Aβ oligomer in a manner analogous to binding of neutral-
izing antibodies [10,36]. Still, we cannot directly interpret
the effect of decreased Aβ monomer by exosomes in vivo
since the effect of monomeric Aβ on synaptic plasticity
had been examined only on hippocampal slice and the dif-
ferent protocol used to induce LTP could also compound
Aβ-induced synaptic alteration [22,37]. Over brain slices
and primarily cultured neurons, Aβ monomer showed
protective effects on LTP and neuronal survival [38,39].
Therefore, the possible outcomes that chronically-decreased
Aβ monomer produces should be further studied. More-
over, the sequestration of Aβ depends upon surface pro-
teins of exosomes such as PrP
C, which supports the idea
that specific involvement of exosomal surface proteins to
capture or immobilize soluble Aβ oligomer at exosomes.
Especially, the ineffectiveness of trypsinized exosomes in
neutralizing synaptotoxicity of Aβ argues against the pos-
sibility of involving exosomal lipids for the exosomes’ pro-
tective effect. Because we examined only the effect of
exosomes in this study, the effect of other small mem-
branous vesicles that also derive from plasma membrane
or other intracellular origins on Aβ-mediated synaptotoxi-
city should be verified further.
The role of PrP
C as a putative receptor for Aβ oligomer,
and its involvement in Aβ-mediated impairment of LTP
has been intensely debated [7,40-42], but there is no con-
troversy regarding the ability of PrP
C to bind Aβ. Multiple
independent studies concluded that PrP
C binds Aβ oligo-
mers specifically and with high affinity [6,7,40,43-45]. In
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C-deficient
cells are significantly less able to protect against Aβ than
PrP
C-containing exosomes. This PrP
C-dependent effect of
exosomes would be due to the high affinity binding of Aβ
to PrP
C. Therefore, exosomes that derived from cell lines
expressing mutated PrP
C at the binding site for Aβ (95-
105 residues of PrP
C) could be used to further verify the
function of PrP
C in detail [7,45]. In this study, we can use
only the exosomes from “immortalized cell lines” of WT
or PrP
C-depleted neurons due to the difficulty to collect
large amount of exosomes from primarily cultured neuron
or from CSF of genetically modified mice. Notably, the
fact that ablation of PrP
C did not completely obviate the
protective effects of exosomes suggests that exosomal pro-
teins other than PrP
C might also contribute to the seques-
tration of toxic Aβ oligomers, as consistent with previous
observation that Aβ binding was only partially reduced to
PrP
C-deficient neurons [7]. To elucidate the full repertoire
of candidate exosomal proteins involved in the interaction
with Aβ and to further understand their molecular mech-
anisms, further screening and functional studies will be
necessary.
It might be informative to examine whether exosomes
in culture medium play a protective role against the
toxic effect of Aβ on primarily cultured neuron. How-
ever, Aβ-induced deficit in synaptic plasticity normally
occurs well before manifest loss of neurons in AD
models [2,4,46]. To establish whether the effects of Aβ
and exosomes on synaptic plasticity are reflected at the
level of cognition, behavioral tests determining their ef-
fect on cognitive function will be required.
In this study, we provide evidence for the neutralizing
action of exosomes against Aβ-induced LTP impairment
using both N2a cell-derived exosomes and human CSF-
derived exosomes. These observations raised an important
question: Do endogenous exosomes normally prevent Aβ-
mediated impairment of synaptic plasticity? However,
demonstration for effects of endogenous exosomes on
AD pathogenesis or Aβ-induced alteration of synaptic
plasticity was very challenging due to the difficulties to
modify the nature and quantity of exosomes in the brain
without any side effects. For example, when we activated
the recycling of endosomes to increase the release of exo-
somes, the manipulation might affect production and re-
lease of Aβ [47]. The amount of exosomes prepared from
human CSF or interstitial fluid of brain has been mea-
sured only in a few studies for its scarcity [48]. Although
we were also unable to quantify the exosome content in a
systematic manner due to the limited supply of fresh CSF,
we did obtain approximately 8 μgo fe x o s o m e sf r o m1 0m l
of human CSF following the purification steps including
density gradient fractionation that normally involves con-
siderable loss of exosomes (up to 60 % of the starting
amount; see ref. Tauro et al. [49]). Accordingly, we esti-
mated~2 μg endogenous exosomes contained in 1 ml of
human CSF as consistence with previous study [48].
Therefore, we surmise that our i.c.v. infusion of 4 μg exo-
somes would yield~4 times the concentration of en-
dogenous exosomes present in rat CSF, assuming that rat
CSF (ranged 500 μl total; see ref. Lai et al. [50]) contained
an exosome content similar to that of human CSF. Import-
antly, 1 μg of CSF-derived exosomes exhibited a significantly
protective effect when co-injected with Aβ-containing
AD brain extracts (Figure 6). Taken together, we specu-
late that exosomes may protect synaptic plasticity
against amyloidogenic insults in situ particularly over
an extended time window. Considering studies indicating
t h ei n c r e a s e dr e l e a s eo fe x o s o m e sb y2 . 5-4f o l d su n d e r
in vitro hypoxia condition [15,51], it is very likely that this
process could be occurred in pathological condition. Even-
tually, exosome-bound Aβ might be taken up by microglia
for degradation in normal condition [16], or they can be
the seed for the plaque formation in pathological condi-
tion [52]. The efficiency of this process may be critical in
determining the onset and progression of AD given the
causal contribution of synaptic failure to the disease and
cognitive decline [2]. Since both Aβ and exosomes are re-
leased from the brain in an activity-dependent manner
[53,54], the dynamic change of exosome concentration in
brain, especially in AD patients, is a subject that we feel
should be explored further.
Conclusions
Collectively, exosomes are able to sequester synaptotoxic
Aβ oligomers via surface proteins such as PrP
C and thereby
rescue LTP from Aβ-mediated impairment in vivo.I m -
portantly, our findings based on exosomes isolated from
human CSF and Aβ from AD brain strongly indicate that
the pathophysiologically relevant forms of Aβ in the brain
can be sequestered by exosomes. Although we were unable
to quantitatively measure the change of total exosome
concentration in the brain after exogenous application, at
the very least we were successful in using human CSF
samples to provide a reasonable and predictive window on
exosome levels in the brain and thus to assess the utility of
this measure as a biomarker for AD. Similarly, when we
can manipulate the levels of endogenous exosomes in a
more precise manner, we will be in a better position to as-
certain their pathophysiological contribution to AD and
perhaps supply exogenous exosomes or artificially engi-
neered forms of lipid vesicles for a therapeutic benefit.
Methods
Animals
Male Wistar rats (250 - 350 g) were used for in vivo re-
cording experiments. They were housed under a 12-hour
light/dark cycle and given ad libitum access to food and
water. The rats were anesthetized with urethane (ethyl
An et al. Molecular Brain 2013, 6:47 Page 9 of 13
http://www.molecularbrain.com/content/6/1/47carbamate, 1.5 g/kg, i.p.). The body temperature was
maintained at 37.4 - 38°C for the duration of the experi-
ments. All procedures for animal experiments were ap-
proved by the ethical review committee of Trinity College
Dublin and the Department of Health and Children,
Ireland and POSTECH (Pohang University of Science &
Technology), Korea and performed in accordance with
the relevant guidelines.
ADDLs preparation
Aβ1-42 (American peptide) was dissolved in 1,1,1,3,3,3-
hexafluoro-2-propanol (Sigma) to a concentration of 1
mM. The solution was allowed to evaporate for 2 h and
then dried in a Speed Vac. The resulting film of peptide
was stored at -20°C or immediately resuspended in di-
methyl sulfoxide (Sigma) to produce a 1 mM solution.
This solution was sonicated for 10 min in a sonic bath,
and then diluted to 100 μM in phenol red-free Ham’s
F12 medium (Life Technology) and incubated for 12 h at
4°C. The resulting solution was then spun at 100,000 g
for 1 h and either used immediately or stored at -80°C
for up to 2 weeks. Monomeric Aβ1-42 was prepared by
dissolving the peptide film to 100 μM in 10 mM NaOH
solution (pH 11).
Isolation of exosomes
N2a cells were grown in exosome-depleted medium
comprising 44.5% DMEM, 44.5% Opti-MEM with 10%
FBS and 1% Penicillin/Streptomycin under a humidified
environment of 5% CO2/95% O2 incubator at 37°C. PrP
C
WT or KO cells (HW8-1 and Hpl3-4, respectively)
established from the primary cultured hippocampal
neuron of Prnp
+/+ and Prnp
-/- mice [27] were grown in
exosome-depleted medium composed of 89% DMEM,
10% FBS and 1% Penicillin/Streptomycin. Exosomes
were prepared as previously described [20] with minor
modifications. In brief, exosome-enriched media was
fractionated by centrifugation (200,000 g × 2 h) on a 5 -
30% of opti-prep gradient (Axis-Shield) in a SW-41 rotor
(Beckman Coulter). 1 ml from each fraction was col-
lected and diluted 1:10 with pre-cooled phosphate-
buffered saline (PBS) and collected by centrifugation for
1 h at 100,000 g. A portion of the resultant pellets were
boiled in 2× sample buffer and used for Western blotting.
Fractions enriched in exosomes were used for subsequent
studies. The amount of exosomes used was expressed in
terms of total protein which was determined using the
Pierce BCA assay kit (Thermo Scientific).
All procedures for collection and usage of human CSF
were approved by the Mater Misericordiae University
Hospital Research Ethics committee, Ireland. CSF was
obtained from a 61-year-old female and a 71-year-old
male donors both of whom were healthy and cognitively
normal. 10 ml of CSF in total was taken by lumbar
puncture from the L3/L4 interspace, and kept on ice.
CSF was used to isolate exosomes within 2 h of collec-
tion, using the procedure described above.
Western blotting
Samples containing Aβ were mixed with 4X NuPAGE®
LDS sample buffer and electrophoresed on NuPAGE®
4 - 12% Bis-Tris gels (Life Technology). Proteins were
transferred onto PVDF membrane (Millipore) and the
membrane blocked using 5% skim-milk solution was
immunoblotted with the anti-Aβ antibody, 6E10 (Cov-
ance). For detection of exosomal proteins, samples were
boiled after being mixed with 5X sample buffer, then
electrophoresed on 10% polyacrylamide SDS gels, trans-
ferred onto PVDF membrane and finally immuno-
blotted with antibodies against Alix (BD Bioscience),
Flotillin-1 (BD Bioscience), PrP
C (ICSM-35, D-Gen),
CD81 (Santa Cruz Biotechnology) or β-actin (Sigma).
Immunoreactive bands were visualized using horserad-
ish peroxidase-conjugated goat anti-mouse IgG second-
ary antibody (1:3000) (Signalway Antibody) and images
were collected by Las-4000 (Fujifilm Life Science). The
western blot images were analyzed using Image J soft-
ware (NIH).
Atomic force microscopy (AFM)
10 μlo f1 0μM ADDLs in PBS was incubated on freshly
cleaved mica for 1 min. The mica was washed twice with
100 μl of deionized water and dried under a gentle
stream of N2 gas. Tapping mode AFM imaging was per-
formed in air using Multimode/Nanoscope IIIa (Digital
instruments) equipped with a J-scanner. The images
were taken with a TESP cantilever (Veeco) at a sample
rate of 0.85 Hz. Section analysis (Nanoscope V) was
employed to measure the z-height of distinct globules
(>50) and the z-height was used as a representative value
for the size of Aβ oligomers [19].
Electron microscopy (EM)
5 μl drops of exosomes (50 μg/ml) were loaded onto
carbon-coated 200 μm copper grids and incubated for
1 min. The samples were then stained with 2% uranyl
acetate for 2 min, and excess solution carefully removed
and the grid left to air dry. Images were captured using an
electron microscope (JEOL) operated at 100 kV.
Dynamic light scattering (DLS) spectroscopy
The sizes of exosomes (10 μgi n1 0 0μl) or ADDLs (10 μM
in 100 μl) were measured by DLS performed with Zetasizer
Nanoseries instrument (Malvern Nano-Zetasizer). The
mean values of particle sizes were obtained from more
than 3 independent preparations.
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Electrodes were made and implanted in anaesthetized
animals as described previously [6]. Briefly, twisted-wire
bipolar electrodes were constructed with Teflon-coated
tungsten wires (62.5 μm inner core diameter, 75 μme x t e r -
nal diameter, A-M Systems). Field excitatory postsynaptic
potentials (fEPSPs) were recorded from the stratum ra-
diatum of the CA1 area of the right dorsal hippocampus
in response to stimulation of the ipsilateral Schaffer
collateral-commissural pathway. Electrode implantation
sites were identified using stereotaxic coordinates relative
to bregma, with the recording site located 3.4 mm poster-
ior to bregma and 2.5 mm right of midline, and the stimu-
lating electrode located 4.2 mm posterior to bregma and
3.8 mm right of midline. The optimal depth of the elec-
trodes was determined using electrophysiological criteria
and verified post-mortem. Test fEPSPs were evoked at a
frequency of 0.033 Hz at the stimulation intensities ad-
justed to elicit fEPSP amplitudes of 40 - 50% of maximum.
The high-frequency stimulation (HFS) protocol for indu-
cing LTP consisted of 10 bursts of 20 stimuli with an
inter-stimulus interval of 5 ms (200 Hz), and an inter-
burst interval of 2 sec. The intensity was increased so as
to give 75% of maximum amplitudes of fEPSPs during the
HFS. The weak HFS consisted of 10 bursts of 10 stimuli
with an inter-stimulus interval of 10 ms (100 Hz), and an
inter-burst interval of 2 sec. The initial slopes of fEPSPs
were measured and the average of ten sweeps was plotted.
Unless otherwise specified, fEPSP slopes (% Baseline) indi-
cate the mean slopes between 170 - 180 min after HFS in
each condition. To infuse samples, a stainless-steel guide
cannula (22 gauge, 0.7 mm outer diameter, 13 mm length)
was implanted above the right lateral ventricle (1 mm lat-
eral to the midline and 4 mm below the surface of the
dura) just prior to electrode implantation. The placement
of the cannula was verified post-mortem with i.c.v. infu-
sion of Indian Blue ink dye.
Binding assays between ADDLs and exosomes
ADDLs were centrifuged for 1 h at 100,000 g prior to in-
cubation with exosomes. The supernatant contained
more than 95% of the starting peptide. 1 μg of this
ADDL supernatant was then added to identical volumes
of purified trypsinized or mock-trypsinized exosomes
(160 μg) and incubated at 37°C for 30 min in 10 ml PBS.
Thereafter, exosomes were separated from the unbound
Aβ by centrifuging for 1 h at 100,000 g. The exosome
pellet was dissolved in 2× sample buffer and 25% of the
mixture used for Western blotting for exosome-bound
Aβ. 25% of the supernatant resulted from 100,000 g cen-
trifugation was collected and used for immunoprecipita-
tion with 6E10/Western blotting for exosome-unbound
Aβ. Mean % of ~12 and 16 kDa Aβ bound to exosomes
(P) relative to total ~12 and 16 kDa Aβ (P +S) was used
for the presentation with bar graph.
Limited trypsinization for surface proteins of exosomes
Exosomes (0.5 mg/ml) were incubated with trypsin (1 mg/ml,
Sigma) for 30 min at 37°C and the reaction was stopped
by addition of a serine protease inhibitor Pefabloc SC™
(4 mg/ml, Sigma). After this treatment, exosomes were
re-isolated by density gradient centrifugation (as described
in the procedures for exosomes isolation). The effect of
trypsin on surface and luminal proteins was verified by as-
sessment of trypsinized- and mock-trypsinized exosomes
with antibodies against PrP
C, CD81 (exosomal surface
proteins) or Alix (luminal protein).
Immunoprecipitation of exosomes
Exosomes were incubated with anti-Flotillin-1 anti-
body (8 μl )a n dp r e - w a s h e dP r o t e i nA / Ga g a r o s eb e a d
(Calbiochem) at 4°C for 6 h. The resulting precipitates
were washed with PBS and 25% of each sample was
used for western blotting.
AD brain extracts
Human tissue was obtained and used in accordance with
local IRB guidelines. A sample of temporal cortex from a
92-year-old woman with a history of dementia and con-
firmed AD pathology was used to prepare water-soluble
extracts and the extracts were examined for the presence
of Aβ as described previously [6]. Briefly, a ~2 g cube of
frozen tissue was thawed on ice, gray matter isolated,
chopped into small pieces with a razor blade and then
homogenized in 5 volumes of ice-cold 20 mM Tris-HCl,
pH 7.4, containing 150 mM NaCl (TBS) with 25 strokes
of a Dounce homogenizer (Fisher). The water-soluble
fraction was separated from the insoluble fraction by
centrifugation at 91,000 g and 4°C in a TLA 55 rotor
(Beckman Coulter) for 78 min and the supernatant was
used for the subsequent studies. To eliminate low-
molecular-weight bioactive molecules and drugs, the
supernatant was exchanged into sterile 50 mM ammonium
acetate, pH 8.5 using a 5 ml Hi-trap desalting column (GE
Healthcare Bio-Sciences). Thereafter the extracts were
divided into 2 parts: one aliquot was immunodepleted
(AD-Aβ
-)o fA β by 3 rounds of 12 h incubations with the
anti-Aβ antibody, AW7 [55], and protein A at 4°C. The
second portion was treated identically, but pre-immune
serum was used instead of AW7 anti-Aβ antiserum and so
produced a “mock”-immunodepleted samples (AD-Aβ
+).
The amount and form of Aβ was analyzed in duplicate
0.3 ml samples by immunoprecipitated with AW7 at a dilu-
tion of 1:80 and by western blotting using a combination of
the C-terminal monoclonal antibodies, 2G3 and 21F12 (each
at a concentration of 1 μg/ml). Detection was achieved using
fluorochrome-coupled anti-mouse secondary antibody
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at 800 nm at a resolution of 169 μmu s i n gaL i - C O R
Odyssey near infrared imaging system (Li-COR Biosciences).
Aβ present in the immunoprecipitates were quantified by
references of known amounts of synthetic Aβ1-42 loadings
(2, 5, 10 ng per well) [55].
Statistical analysis
LTP was expressed as mean ±SEM% of baseline slopes
of fEPSPs recorded over at least a 30 min baseline period.
Statistical comparisons used paired Student t-tests to
compare within single groups of animals for baseline or
LTP results whereas unpaired t-tests were employed to
compare the LTP between two groups. In the case of mul-
tiple comparisons, one-way ANOVA with post hoc Tukey
test was used. The results from dynamic light scattering
or immunoblots were expressed as mean±SEM % and
compared with Mann-Whitney U test. Statistical signifi-
cance between groups is expressed as N.S., not significant;
*, P<0.05; **, P<0. 01 ;or* ** ,P<0. 00 1.
Additional file
Additional file 1: Figure S1. Exosomes neutralize synaptic-plasticity-
disrupting activity of Aβ assemblies in vivo.
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